Oramed Pharmaceuticals Company Profile (NASDAQ:ORMP)

About Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals logoOramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed's flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed's delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company's products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ORMP
  • CUSIP: N/A
  • Web: www.oramed.com
Capitalization:
  • Market Cap: $127.88 million
  • Outstanding Shares: 13,320,000
Average Prices:
  • 50 Day Moving Avg: $8.43
  • 200 Day Moving Avg: $7.66
  • 52 Week Range: $5.70 - $10.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.28
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.19 million
  • Price / Sales: 58.45
  • Book Value: $1.49 per share
  • Price / Book: 6.45
Profitability:
  • EBIDTA: ($11,450,000.00)
  • Return on Equity: -54.96%
  • Return on Assets: -29.63%
Debt:
  • Current Ratio: 5.24%
  • Quick Ratio: 5.24%
Misc:
  • Average Volume: 51,850 shs.
  • Beta: 0.37
  • Short Ratio: 5.93
 

Frequently Asked Questions for Oramed Pharmaceuticals (NASDAQ:ORMP)

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

When will Oramed Pharmaceuticals make its next earnings announcement?

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November, 24th 2017. View Earnings Estimates for Oramed Pharmaceuticals.

Where is Oramed Pharmaceuticals' stock going? Where will Oramed Pharmaceuticals' stock price be in 2017?

1 analysts have issued twelve-month target prices for Oramed Pharmaceuticals' stock. Their predictions range from $25.00 to $25.00. On average, they expect Oramed Pharmaceuticals' share price to reach $25.00 in the next year. View Analyst Ratings for Oramed Pharmaceuticals.

Who are some of Oramed Pharmaceuticals' key competitors?

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the folowing people:

  • Harold Jacob M.D., Chairman of the Board
  • Nadav Kidron, President, Chief Executive Officer, Director
  • Hilla Eisenberg, Chief Financial Officer, Treasurer, Secretary
  • Joshua Hexter, Chief Operating Officer, Vice President - Business Development
  • Miriam Kidron Ph.D., Chief Medical and Technology Officer, Director
  • Ronald Edward Law, Chief Strategy Officer
  • Roy Eldor M.D, Director
  • Ele Ferrannini M.D, Director
  • Avram Hershko M.D., Ph.D., Director
  • Michael Berelowitz M.D.,, Independent Director

Who owns Oramed Pharmaceuticals stock?

Oramed Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include PNC Financial Services Group Inc. (0.16%), Virtu KCG Holdings LLC (0.12%) and Wells Fargo & Company MN (0.11%). Company insiders that own Oramed Pharmaceuticals stock include Michael Berelowitz, Miriam Kidron, Nadav Kidron and Xiaopeng Li. View Institutional Ownership Trends for Oramed Pharmaceuticals.

Who bought Oramed Pharmaceuticals stock? Who is buying Oramed Pharmaceuticals stock?

Oramed Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC and Wells Fargo & Company MN. Company insiders that have bought Oramed Pharmaceuticals stock in the last two years include Nadav Kidron and Xiaopeng Li. View Insider Buying and Selling for Oramed Pharmaceuticals.

How do I buy Oramed Pharmaceuticals stock?

Shares of Oramed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of Oramed Pharmaceuticals stock can currently be purchased for approximately $9.61.


MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Oramed Pharmaceuticals (NASDAQ:ORMP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.00 (160.15% upside)

Analysts' Ratings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017HC WainwrightSet Price TargetBuy$25.00LowView Rating Details
8/21/2016Rodman & RenshawReiterated RatingBuy$25.00N/AView Rating Details
5/26/2016FBR & CoBoost Price TargetOutperform$15.00 -> $20.00N/AView Rating Details
5/18/2016AegisReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)
Current Year EPS Consensus Estimate: $-0.9 EPS
Next Year EPS Consensus Estimate: $-1.53 EPS

Dividends

Dividend History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Insider Ownership Percentage: 27.50%
Institutional Ownership Percentage: 1.34%
Insider Trades by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)
Institutional Ownership by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)
Insider Trades by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2017Xiaopeng LiDirectorBuy89,636$8.50$761,906.00View SEC Filing  
4/19/2017Miriam KidronInsiderSell52,814$6.33$334,312.62View SEC Filing  
5/12/2016Nadav KidronCEOBuy1,000$6.95$6,950.00View SEC Filing  
12/30/2015Miriam KidronCTOSell50,000$8.90$445,000.00View SEC Filing  
12/9/2015Michael BerelowitzDirectorSell700$9.44$6,608.00View SEC Filing  
12/8/2015Michael BerelowitzDirectorSell1,300$8.70$11,310.00View SEC Filing  
3/19/2015Nadav KidronCEOBuy2,600$3.88$10,088.00View SEC Filing  
9/11/2014Miriam KidronCTOSell31,699$8.41$266,588.59View SEC Filing  
9/10/2014Miriam KidronCTOSell23,000$8.40$193,200.00View SEC Filing  
9/4/2014Miriam KidronCTOSell8,301$9.41$78,112.41View SEC Filing  
6/6/2014Regals Capital Management LpMajor ShareholderBuy2,252$4.44$9,998.88View SEC Filing  
3/31/2014Michael BerelowitzDirectorSell9,434$10.50$99,057.00View SEC Filing  
3/25/2014Regals Capital Management Lpmajor shareholderBuy75,000$10.62$796,500.00View SEC Filing  
2/6/2014Regals Capital Management Lpmajor shareholderBuy51,292$15.61$800,668.12View SEC Filing  
7/10/2013Regals Capital Management LpMajor ShareholderBuy6,630$7.40$49,062.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Oramed Pharmaceuticals (NASDAQ:ORMP)
Latest Headlines for Oramed Pharmaceuticals (NASDAQ:ORMP)
Source:
DateHeadline
americanbankingnews.com logoCritical Analysis: Portola Pharmaceuticals (PTLA) versus Oramed Pharmaceuticals (ORMP)
www.americanbankingnews.com - September 12 at 2:26 AM
americanbankingnews.com logoOramed Pharmaceuticals Inc. (ORMP) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - September 6 at 11:02 PM
streetinsider.com logoOramed Pharma (ORMP) Says FDA Meeting Provides BLA Guidance on ORMD-0801
www.streetinsider.com - September 6 at 7:16 AM
finance.yahoo.com logoOramed Announces Successful Meeting with FDA for Oral Insulin
finance.yahoo.com - September 6 at 7:16 AM
finance.yahoo.com logoOramed (ORMP): Successful Meeting with FDA for Oral Insulin
finance.yahoo.com - September 6 at 7:16 AM
americanbankingnews.com logoOramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - September 4 at 7:30 AM
finance.yahoo.com logoOramed to Present at the Rodman & Renshaw Global Investment Conference
finance.yahoo.com - August 30 at 7:40 AM
americanbankingnews.com logoOramed Pharmaceuticals Inc. (ORMP) Expected to Announce Quarterly Sales of $610,000.00
www.americanbankingnews.com - August 17 at 9:48 AM
americanbankingnews.com logoOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Director Purchases $761,906.00 in Stock
www.americanbankingnews.com - August 3 at 7:52 PM
americanbankingnews.com logoOramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expected to Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - July 29 at 7:21 AM
americanbankingnews.com logo Analysts Anticipate Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Will Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - July 27 at 8:10 PM
streetinsider.com logoOramed Pharma (ORMP) CFO Resigns - StreetInsider.com
www.streetinsider.com - July 22 at 7:22 AM
prnewswire.com logoOramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs - PR Newswire (press release)
www.prnewswire.com - July 19 at 1:09 AM
finance.yahoo.com logoOramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs
finance.yahoo.com - July 19 at 1:09 AM
finance.yahoo.com logoOramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017
finance.yahoo.com - July 13 at 7:42 AM
rttnews.com logoORMP To Meet With FDA, Second Time's No Charm For OCUL, Panel Backs PFE
www.rttnews.com - July 12 at 6:42 AM
finance.yahoo.com logoOramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program
finance.yahoo.com - July 12 at 6:42 AM
finance.yahoo.com logoOramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017
finance.yahoo.com - July 11 at 6:25 AM
americanbankingnews.com logoHead to Head Review: Oramed Pharmaceuticals (ORMP) vs. ImmunoGen (IMGN)
www.americanbankingnews.com - July 10 at 10:28 PM
finance.yahoo.com logoOramed reports 3Q loss
finance.yahoo.com - July 7 at 7:54 AM
finance.yahoo.com logoOramed Announces Dual-Listing on Tel Aviv Stock Exchange
finance.yahoo.com - July 5 at 9:21 AM
finance.yahoo.com logoOramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule
finance.yahoo.com - June 27 at 7:12 PM
americanbankingnews.com logoShort Interest in Oramed Pharmaceuticals Inc. (ORMP) Expands By 1.9%
www.americanbankingnews.com - June 15 at 7:12 AM
finance.yahoo.com logoOramed Plans Secondary Listing in Tel Aviv Soon, CEO Kidron Says
finance.yahoo.com - June 12 at 6:45 PM
americanbankingnews.com logoOramed Pharmaceuticals, Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00
www.americanbankingnews.com - June 9 at 1:31 PM
americanbankingnews.com logo Analysts Anticipate Oramed Pharmaceuticals, Inc. (ORMP) Will Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - June 7 at 2:16 PM
prnewswire.com logoOramed to Present at the American Diabetes Association 77th Scientific Sessions - PR Newswire (press release)
www.prnewswire.com - June 6 at 7:49 PM
finance.yahoo.com logoOramed to Present at the American Diabetes Association 77th Scientific Sessions
finance.yahoo.com - June 6 at 7:49 PM
prnewswire.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for - PR Newswire (press release)
www.prnewswire.com - June 5 at 7:40 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - June 5 at 7:40 PM
americanbankingnews.com logoOramed Pharmaceuticals, Inc. (ORMP) PT Set at $25.00 by HC Wainwright
www.americanbankingnews.com - May 23 at 8:43 PM
finance.yahoo.com logoOramed to Present at Conferences Next Week
finance.yahoo.com - May 19 at 11:50 AM
streetinsider.com logoOramed Pharma (ORMP) Announces Canadian Patent for GLP-1 Analog Capsul - StreetInsider.com
www.streetinsider.com - May 10 at 11:49 AM
streetinsider.com logoOramed Pharma (ORMP) Announces Canadian Patent for GLP-1 Analog Capsul
www.streetinsider.com - May 9 at 11:16 AM
finance.yahoo.com logoOramed Granted Canadian Patent for GLP-1 Analog Capsule
finance.yahoo.com - May 9 at 11:16 AM
finance.yahoo.com logoOramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017
finance.yahoo.com - May 5 at 7:20 PM
finance.yahoo.com logoOramed (ORMP) to Conduct Human Study for New Oral Leptin Capsule
finance.yahoo.com - May 2 at 4:51 PM
prnewswire.com logoOramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule - PR Newswire (press release)
www.prnewswire.com - May 2 at 11:10 AM
finance.yahoo.com logoOramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule
finance.yahoo.com - May 2 at 11:10 AM
finance.yahoo.com logoOramed Gaining Strength in Oral Diabetes Market
finance.yahoo.com - May 1 at 5:58 PM
streetinsider.com logoOramed Pharma (ORMP) Says EPO Granted Patent for Combination Oral Insulin and GLP-1 Analog Capsule - StreetInsider.com
www.streetinsider.com - April 21 at 12:12 AM
finance.yahoo.com logoOramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule - Yahoo Finance
finance.yahoo.com - April 20 at 9:04 AM
finance.yahoo.com logoOramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule
finance.yahoo.com - April 20 at 9:04 AM
americanbankingnews.com logoInsider Selling: Oramed Pharmaceuticals, Inc. (ORMP) Insider Sells 52,814 Shares of Stock
www.americanbankingnews.com - April 19 at 7:53 PM
marketbeat.com logoOramed reports 2Q loss
marketbeat.com - April 6 at 5:04 AM
finance.yahoo.com logoOramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
finance.yahoo.com - March 22 at 9:02 AM
streetinsider.com logoOramed Pharma (ORMP) Appoints Dr. Ronald Law as CSO - StreetInsider.com
www.streetinsider.com - March 21 at 11:12 AM
finance.yahoo.com logoOramed Appoints Dr. Ronald Law as Chief Strategy Officer
finance.yahoo.com - March 21 at 11:12 AM
biz.yahoo.com logoORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 21 at 11:12 AM
seekingalpha.com logoHere's Where Oramed Fits Into The Diabetes Space
seekingalpha.com - February 17 at 4:45 PM

Social

Chart

Oramed Pharmaceuticals (ORMP) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff